Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014.
OBJECTIVE
To discuss the need for revision of the "core set" of domains to be included for assessment in psoriatic arthritis (PsA) randomized controlled trials and longitudinal observational studies, review work undertaken since the 2012 meeting of Outcome Measures for Rheumatology 11 (OMERACT 11) to include patient perspectives in this revision, and reassess proposed composite measures in the context of new research data and the OMERACT Filter 2.0 framework.


METHODS
The OMERACT 12 (2014) PsA working group presented work completed over the last 2 years to incorporate patient involvement in PsA outcomes research, review the endorsed PsA core set based on the patient perspective as well as new research findings, and further develop PsA responder indices. Breakout groups then discussed 2 topics: (1) the need to revise the PsA core set, and opportunities to add, move, or merge existing domains to improve existing redundancy; and (2) how to incorporate the core set in a composite index. Breakout groups fed back to the working group before participant voting.


RESULTS
Meeting participants endorsed the need to revise the PsA core set according to the OMERACT Filter 2.0 framework (100%), and the inclusion of disease impact (94%) and fatigue (72%) in the inner circle. Breakout group feedback suggested the core set revision was an opportunity to consolidate pathophysiologic aspects such as arthritis, enthesitis, dactylitis, spondylitis as "inflammatory musculoskeletal disease," and nail and skin psoriasis as "psoriasis activity."


CONCLUSIONS
Future work will focus on updating the PsA core set and development of responder indices with ongoing, meaningful involvement of patient research partners.
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
William
W
Tillett
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Lihi
L
Eder
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Niti
N
Goel
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Maarten
M
De Wit
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Dafna D
DD
Gladman
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Oliver
O
FitzGerald
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Willemina
W
Campbell
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Philip S
PS
Helliwell
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Laure
L
Gossec
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Ana-Maria
AM
Orbai
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Alexis
A
Ogdie
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Vibeke
V
Strand
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Neil J
NJ
McHugh
From the Royal National Hospital for Rheumatic Diseases, Bath, UK; Toronto Western Hospital; Psoriatic Arthritis Program, University Health Network, Toronto Western Research Institute, Toronto, Ontario, Canada; St. Vincent's University Hospital, Dublin, Ireland; Quintiles; Duke University School of Medicine; Durham, North Carolina, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Chapel Allerton Hospital, Leeds, UK; Sorbonne Universités, Université Pierre et Marie Curie-Paris 6 (UPMC Univ Paris 6), Institut Pierre Louis d'Epidémiologie et de Santé Publique; AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, Maryland; Division of Immunology/Rheumatology, Stanford University School of Medicine, Portola Valley, California, USA; University of Bath, Bath, UK; Swedish Medical Center, University of Washington, Seattle, Washington; Hospital of the University of Pennsylvania (HUP), Philadelphia, Pennsylvania, USA.W. Tillett, MB, ChB, BSc, MRCP, PhD, Research Fellow, Royal National Hospital for Rheumatic Diseases; L. Eder, MD, PhD, Postdoctoral Research Fellow, Toronto Western Hospital; M. de Wit, PhD, OMERACT Patient Research Partner, The Netherlands; D.D. Gladman, MD, FRCPC, Director, Psoriatic Arthritis Program, University Health Network, Senior Scientist, Toronto Western Research Institute; O. FitzGerald, MD, FRCPI, FRCP( UK), Consultant Rheumatologist and Newman Clinical Research Professor, St. Vincent's University Hospital; N. Goel, MD, OMERACT Patient Research Partner, Quintiles, and Duke University School of Medicine; W. Campbell, BEd, LLB, OMERACT Patient Research Partner; P.S. Helliwell, DM, PhD, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 6, Institut Pierre Louis d'Epidémiologie et de Sant
Philip J
PJ
Mease
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000175:diagnosis / Q000188:drug therapy*; D003245:Consensus Statements as Topic; D005260:Female; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D064887:Observational Studies as Topic; D017063:Outcome Assessment, Health Care; D010358:Patient Participation; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D014861:Washington
D018501:Antirheumatic Agents
OMERACT; OUTCOME MEASUREMENT; PATIENT PARTICIPATION; PSORIATIC ARTHRITIS